PX1 Research provides certified, high-purity Semax nasal formulations engineered strictly for qualified laboratory and preclinical investigation. Every batch undergoes rigorous RP-HPLC and mass spectrometry testing to guarantee verified identity, exact concentration, and minimal endotoxin levels for reliable experimental reproduction.
PX1 Research provides certified, high-purity Semax nasal formulations engineered strictly for qualified laboratory and preclinical investigation. Every batch undergoes rigorous RP-HPLC and mass spectrometry testing to guarantee verified identity, exact concentration, and minimal endotoxin levels for reliable experimental reproduction.
To buy Semax nasal solution for scientific experimentation, researchers require validated purity, lot-specific analytical verification, and reliable delivery. PX1 Research supplies high-purity Semax intranasal formulation manufactured in USA-based GMP-compliant facilities, complete with ISO 17025 third-party Certificate of Analysis (COA) documentation covering high-performance liquid chromatography (HPLC) and mass spectrometry (MS) screening.
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, specifically ACTH(4-10), modified with a C-terminal Pro-Gly-Pro tripeptide sequence to significantly enhance enzymatic stability. When procuring this compound for laboratory setups, investigators must rely on suppliers that enforce strict quality control, including Limulus Amebocyte Lysate (LAL) testing for endotoxin contamination, ensuring that in vitro and in vivo models remain unconfounded by biological impurities.
Researchers evaluating options across our comprehensive catalog of research peptides will find that PX1 Research maintains stringent cold-chain packaging and same-day dispatch from our California and Arizona fulfillment hubs to preserve peptide integrity from synthesis to laboratory receipt.
Semax (sequence: Met-Glu-His-Phe-Pro-Gly-Pro) is a regulatory neuropeptide analog modeled after the N-terminal core sequence of ACTH. The native ACTH(4-10) sequence exhibits transient signaling activity in central nervous system tissues but suffers from an extremely short half-life due to rapid cleavage by endogenous peptidases. To overcome these pharmacokinetic limitations in preclinical research, bio-organic chemists appended a C-terminal tripeptide (Proline-Glycine-Proline).
This structural modification dramatically alters the peptide's enzymatic degradation kinetics. The Pro-Gly-Pro motif protects the primary sequence against aminopeptidase and carboxypeptidase degradation, extending the peptide's structural stability in aqueous solution and biological fluids. In preclinical research settings, this stabilization allows for sustained interaction with target neural receptors and cellular pathways without requiring chemical modifications that alter native signaling properties.
When analyzing Semax via mass spectrometry, the chemical formula $C_{37}H_{51}N_{9}O_{10}S$ yields a exact monoisotopic mass of 813.35 g/mol. Quality control at PX1 Research confirms both this molecular mass and the peptide's structural purity, ensuring that every vial of Semax research peptide conforms to strict reference standards before release.
The primary focus of empirical literature surrounding Semax involves its influence on neurotrophic factors, specifically Brain-Derived Neurotrophic Factor (BDNF) and its primary receptor, Tropomyosin receptor kinase B (TrkB). In vitro assays using primary neuronal cultures demonstrate that exposure to Semax results in a rapid upregulation of BDNF gene expression, alongside an increase in nerve growth factor (NGF) transcript levels.
Preclinical rodent models suggest that this upregulation of neurotrophin expression triggers downstream intracellular cascades, including the MAPK/ERK and PI3K/Akt signaling pathways. These pathways play documented roles in neuronal survival, dendritic spine remodeling, and synaptic plasticity. Under conditions of induced hypoxia or cellular oxidative stress, preclinical data indicate that Semax exposure helps attenuate apoptotic signaling by stabilizing mitochondrial membrane potential and downregulating pro-inflammatory cytokine expression.
Furthermore, transcriptomic profiling in animal models of cerebral ischemia reveals that Semax administration influences the expression of over 100 genes related to vascular tone, extracellular matrix remodeling, and immune response modulation. These multi-target effects make Semax a compelling subject for studies investigating focal ischemic injury, neurodegenerative mechanisms, and neuroprotective cell signaling.
In neurobiological and peptidomimetic research, Semax is frequently compared to other synthetic regulatory peptides, most notably Selank nasal solution and the synthetic neurotrophic compound P21 peptide. While both Semax and Selank share a C-terminal Pro-Gly-Pro stabilizing tail, their core amino acid sequences and primary physiological targets differ significantly. Semax is an ACTH(4-10) analog focused predominantly on BDNF upregulation, dopaminergic signaling, and ischemic protection, whereas Selank is derived from the immunomodulatory peptide Tuftsin and acts primarily on enkephalin degradation pathways and GABAergic neurotransmission.
Another relevant benchmark in regenerative research is BPC-157 research peptide, which operates via distinct angiogenic and tissue repair pathways outside the central nervous system ACTH framework. Understanding these distinct mechanisms allows laboratory directors to select the appropriate compound or comparative control for specific experimental designs.
The table below outlines the key structural and mechanistic distinctions among these common research compounds:
Intranasal administration is the primary route evaluated in non-human primate and rodent studies investigating central nervous system targeting of regulatory peptides. The nasal cavity provides a direct olfactory and trigeminal pathway that bypasses the blood-brain barrier (BBB), allowing high-molecular-weight hydrophilic peptides to access the brain parenchyma without peripheral systemic degradation.
Preclinical pharmacokinetic studies utilizing radiolabeled Semax show rapid appearance of intact peptide in the olfactory bulb, brainstem, cerebral cortex, and hippocampus within 15 to 30 minutes following intranasal instillation. This direct nose-to-brain transport avoids first-pass hepatic metabolism and reduces systemic exposure, providing a highly focused model for central nervous system neuroprotection studies.
For laboratory setups utilizing nasal delivery systems, fluid dynamics, droplet size, and solution viscosity are critical parameters. PX1 Research formulates its nasal solutions using sterile, buffered saline engineered to maintain optimal osmolarity and pH, preventing degradation of the peptide sequence while ensuring reproducible atomization in specialized lab metering devices.
When purchasing peptides for rigorous scientific inquiry, analytical purity is non-negotiable. Substandard peptides containing truncated sequences, residual reagents, or heavy metal contaminants introduce confounding variables that invalidate experimental data. PX1 Research adheres to an uncompromised quality assurance framework where every batch undergoes independent testing at an accredited ISO 17025 laboratory.
Purity is assessed using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). A sharp, single peak at the characteristic retention time confirms a chromatographic purity exceeding 99.0%. Mass identity is verified simultaneously through Electrospray Ionization Mass Spectrometry (ESI-MS), confirming that the observed mass matches the theoretical molecular weight of Semax without chemical adducts or degradation products.
Crucially for neuronal and microglial cell culture models, endotoxin content is quantified using the Limulus Amebocyte Lysate (LAL) assay. PX1 Research enforces a strict limit of <0.05 EU/mg, far below industry standard thresholds. Excess endotoxins (lipopolysaccharides) induce robust inflammatory responses in glia, which can obscure experimental findings related to peptide-mediated neuroprotection. Full lot-traceable Certificates of Analysis are publicly available for every product across our research peptides catalog.
Maintaining structural integrity during transit and storage is essential for bio-active peptides like Semax. Lyophilized and pre-formulated liquid peptides are sensitive to ambient temperature fluctuations, direct ultraviolet light exposure, and mechanical agitation, which can induce physical aggregation or peptide bond hydrolysis.
Upon receipt at the research facility, intact Semax nasal solutions should be stored under refrigerated conditions ($2^\circ\text{C}$ to $8^\circ\text{C}$) for immediate short-term use, or frozen at $-20^\circ\text{C}$ for extended preservation. Repeated freeze-thaw cycles must be avoided, as ice crystal formation can shear peptide bonds and compromise solution concentration. Researchers should aliquot stock solutions into sterile, single-use microcentrifuge tubes under a laminar flow hood if multiple experimental trials are planned.
When working with nasal metering units in laboratory setups, maintaining sterile technique is imperative. Avoid contacting the nozzle tip to unsterile surfaces or cell culture media to prevent bacterial growth, which could rapidly degrade the peptide sequence through secreted bacterial proteases.
PX1 Research is an established USA-based supplier dedicated exclusively to supporting academic institutions, biotechnology organizations, and contract research organizations (CROs). We understand that research schedules depend on consistent product availability, rigorous lot consistency, and rapid delivery.
All orders placed before 3:00 PM EST Monday through Friday are dispatched same-day from our dual fulfillment hubs in California and Arizona. Packages are shipped in temperature-controlled, insulated containers to preserve stability during transit across domestic and international research facilities.
For laboratories requiring high-volume supplies or custom synthesis batches, PX1 Research offers structured procurement through our wholesale peptide program. Institutional accounts benefit from dedicated account management, custom lot reservations, and bulk pricing schedules tailored to long-term study protocols.
What is Semax Nasal and how is it classified in research?
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, specifically ACTH(4-10), with a C-terminal Pro-Gly-Pro tripeptide addition. In scientific literature, it is classified as a regulatory neuropeptide and investigated in preclinical models for its neurotrophic and neuroprotective properties.
Why is the intranasal route studied for Semax delivery in preclinical settings?
Intranasal delivery allows peptides to bypass the blood-brain barrier via direct transport pathways along the olfactory and trigeminal nerve routes. Preclinical studies evaluate this route because it achieves rapid central nervous system distribution without systemic degradation or hepatic first-pass metabolism.
How does PX1 Research verify the purity of Semax Nasal products?
Every lot of Semax undergoes rigorous third-party testing at an ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight verification. Certificates of Analysis are provided with each batch.
What are the endotoxin limits for PX1 Research Semax nasal formulations?
PX1 Research enforces an industry-leading endotoxin limit of less than 0.05 EU/mg, verified via Limulus Amebocyte Lysate (LAL) testing. Low endotoxin levels are vital to ensure in vitro cellular assays and neural models are not confounded by inflammatory contaminants.
How should Semax Nasal solutions be stored in the laboratory?
Unopened liquid formulations should be stored refrigerated at 2°C to 8°C. For long-term storage, solutions or aliquots should be kept at -20°C or colder to prevent peptide hydrolysis. Repeated freeze-thaw cycles should be strictly avoided.
How does Semax differ from Selank in experimental models?
While both contain a Pro-Gly-Pro stabilizing sequence, Semax is derived from ACTH(4-10) and primarily affects BDNF upregulation and neurotrophic pathways. Selank is derived from Tuftsin and focuses on GABAergic pathways and enkephalin degradation. Both are available for comparative studies through PX1 Research.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities. Orders are packed in climate-controlled packaging and shipped same-day (Monday through Friday) from our state-of-the-art fulfillment facilities located in California and Arizona.
Is Semax approved for human consumption or clinical therapy?
No. Semax products provided by PX1 Research are strictly sold as research chemicals for laboratory, in vitro, and preclinical experimental use only. They are not intended for human or animal medical use, treatment, diagnosis, or administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.